120 related articles for article (PubMed ID: 38728412)
1. A lactate-SREBP2 signaling axis drives tolerogenic dendritic cell maturation and promotes cancer progression.
Plebanek MP; Xue Y; Nguyen YV; DeVito NC; Wang X; Holtzhausen A; Beasley GM; Theivanthiran B; Hanks BA
Sci Immunol; 2024 May; 9(95):eadi4191. PubMed ID: 38728412
[TBL] [Abstract][Full Text] [Related]
2. A SREBF2-dependent gene program drives an immunotolerant dendritic cell population during cancer progression.
Plebanek MP; Xue Y; Nguyen YV; DeVito NC; Wang X; Holtzhausen A; Beasley GM; Yarla N; Thievanthiran B; Hanks BA
bioRxiv; 2023 Apr; ():. PubMed ID: 37162965
[TBL] [Abstract][Full Text] [Related]
3. Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy.
Holtzhausen A; Zhao F; Evans KS; Tsutsui M; Orabona C; Tyler DS; Hanks BA
Cancer Immunol Res; 2015 Sep; 3(9):1082-95. PubMed ID: 26041736
[TBL] [Abstract][Full Text] [Related]
4. HDAC9 deficiency promotes tumor progression by decreasing the CD8
Ning Y; Ding J; Sun X; Xie Y; Su M; Ma C; Pan J; Chen J; Jiang H; Qi C
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554611
[TBL] [Abstract][Full Text] [Related]
5. Modulation of lactate-lysosome axis in dendritic cells by clotrimazole potentiates antitumor immunity.
Wang Z; Xu F; Hu J; Zhang H; Cui L; Lu W; He W; Wang X; Li M; Zhang H; Xiong W; Xie C; Liu Y; Zhou P; Liu J; Huang P; Qin XF; Xia X
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016722
[TBL] [Abstract][Full Text] [Related]
6. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
[TBL] [Abstract][Full Text] [Related]
7. Activation of p38 mitogen-activated protein kinase drives dendritic cells to become tolerogenic in ret transgenic mice spontaneously developing melanoma.
Zhao F; Falk C; Osen W; Kato M; Schadendorf D; Umansky V
Clin Cancer Res; 2009 Jul; 15(13):4382-90. PubMed ID: 19549770
[TBL] [Abstract][Full Text] [Related]
8. The transcription factor RBP-J-mediated signaling is essential for dendritic cells to evoke efficient anti-tumor immune responses in mice.
Feng F; Wang YC; Hu XB; Liu XW; Ji G; Chen YR; Wang L; He F; Dou GR; Liang L; Zhang HW; Han H
Mol Cancer; 2010 Apr; 9():90. PubMed ID: 20420708
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
[TBL] [Abstract][Full Text] [Related]
10. Bypassing STAT3-mediated inhibition of the transcriptional regulator ID2 improves the antitumor efficacy of dendritic cells.
Li HS; Liu C; Xiao Y; Chu F; Liang X; Peng W; Hu J; Neelapu SS; Sun SC; Hwu P; Watowich SS
Sci Signal; 2016 Sep; 9(447):ra94. PubMed ID: 27678219
[TBL] [Abstract][Full Text] [Related]
11. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment.
Chelvanambi M; Fecek RJ; Taylor JL; Storkus WJ
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33526609
[TBL] [Abstract][Full Text] [Related]
12. Conversion of tolerogenic CD4-8- dendritic cells to immunogenic ones inducing efficient antitumor immunity.
Zhang X; Moyana T; Quereshi M; Xiang J
Cancer Biother Radiopharm; 2006 Feb; 21(1):74-80. PubMed ID: 16480334
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
14. Hypofractionated radiotherapy combined with lenalidomide improves systemic antitumor activity in mouse solid tumor models.
Onyshchenko K; Luo R; Rao X; Zhang X; Gaedicke S; Grosu AL; Firat E; Niedermann G
Theranostics; 2024; 14(6):2573-2588. PubMed ID: 38646638
[No Abstract] [Full Text] [Related]
15. Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy.
Prokopi A; Tripp CH; Tummers B; Hornsteiner F; Spoeck S; Crawford JC; Clements DR; Efremova M; Hutter K; Bellmann L; Cappellano G; Cadilha BL; Kobold S; Boon L; Ortner D; Trajanoski Z; Chen S; de Gruijl TD; Idoyaga J; Green DR; Stoitzner P
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33408092
[TBL] [Abstract][Full Text] [Related]
16. Melanoma cell lysate induces CCR7 expression and in vivo migration to draining lymph nodes of therapeutic human dendritic cells.
González FE; Ortiz C; Reyes M; Dutzan N; Patel V; Pereda C; Gleisner MA; López MN; Gutkind JS; Salazar-Onfray F
Immunology; 2014 Jul; 142(3):396-405. PubMed ID: 24673602
[TBL] [Abstract][Full Text] [Related]
17. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells.
Chen Z; Moyana T; Saxena A; Warrington R; Jia Z; Xiang J
Int J Cancer; 2001 Aug; 93(4):539-48. PubMed ID: 11477558
[TBL] [Abstract][Full Text] [Related]
18. Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma.
Roberts EW; Broz ML; Binnewies M; Headley MB; Nelson AE; Wolf DM; Kaisho T; Bogunovic D; Bhardwaj N; Krummel MF
Cancer Cell; 2016 Aug; 30(2):324-336. PubMed ID: 27424807
[TBL] [Abstract][Full Text] [Related]
19. Twist1 promotes dendritic cell-mediated antitumor immunity.
Luo Y; Chen J; Liu M; Chen S; Su X; Su J; Zhao C; Han Z; Shi M; Ma X; Huang H
Exp Cell Res; 2020 Jul; 392(2):112003. PubMed ID: 32278689
[TBL] [Abstract][Full Text] [Related]
20. Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells.
Stoitzner P; Green LK; Jung JY; Price KM; Atarea H; Kivell B; Ronchese F
Cancer Immunol Immunother; 2008 Nov; 57(11):1665-73. PubMed ID: 18311487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
